The aim of this study was to investigate the anti-tumour activity of temozolomide in patients with malignant pleural mesothelioma. 27 chemotherapy-naïve patients with histologically-proven malignant mesothelioma were treated with temozolomide 200 mg/m 2/day, given orally on days 1-5 of each 28-day cycle. Therapy continued up to 10 cycles unless disease progression or excessive toxicity mandated discontinuation. Toxicity, symptom improvement and pain intensity were regularly assessed. With a median relative dose intensity of 97%, toxicity was moderate with grade 3 or more nausea, vomiting, thrombocytopenia, leucocytopenia, neutropenia, febrile leucocytopenia, arthralgia, infection and fever with infection occurring in 13, 13, 10, 3, 7 and 3% of patients for the remaining events, respectively. Overall, 1 objective response was observed (response rate 4%, 95% Confidence Interval (CI): 0.1-19). Median survival was 8.2 months. Symptom assessment showed no improvement and an increase of pain was observed during the study. Thus, oral temozolomide is an inactive agent in malignant mesothelioma.

, , , ,
doi.org/10.1016/S0959-8049(01)00428-2, hdl.handle.net/1765/66534
European Journal of Cancer
Department of Pulmonology

van Meerbeeck, J.P, Baas, P, Debruyne, C, Smit, E.F, van Klaveren, R.J, Galdermans, D, … Giaccone, G. (2002). A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. European Journal of Cancer, 38(6), 779–783. doi:10.1016/S0959-8049(01)00428-2